New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
10:01 EDTTTM, QSII, TV, BRO, RUSHA, PHG, LLY, AEGN, RXN, PNR, CTCMOn The Fly: Analyst Downgrade Summary
Aegion (AEGN) downgraded to Neutral from Buy at Sidoti... Brown & Brown (BRO) downgraded to Neutral from Buy at Compass Point... CTC Media (CTCM) downgraded to Underperform from Neutral at Credit Suisse... Eli Lilly (LLY) downgraded to Neutral from Buy at MKM Partners... Grupo Televisa (TV) downgraded to Underperform from Neutral at BofA/Merrill... Pentair (PNR) downgraded to Neutral from Outperform at Wedbush... Philips (PHG) downgraded to Sector Perform from Outperform at RBC Capital... Quality Systems (QSII) downgraded to Underweight from Equal Weight at Morgan Stanley... Rexnord (RXN) downgraded at BofA/Merrill... Rush Enterprises (RUSHA) downgraded to Equal Weight from Overweight at Stephens... Tata Motors (TTM) downgraded to Neutral from Outperform at Credit Suisse.
News For AEGN;BRO;CTCM;LLY;TV;PNR;PHG;QSII;RXN;RUSHA;TTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 17, 2014
05:19 EDTPHGPhilips to acquire Volcano for $18.00 per share
December 16, 2014
19:01 EDTPNRIn-Situ Inc. announces divestiture of PR Aqua Supplies to Pentair
Subscribe for More Information
14:48 EDTLLYEli Lilly's CYRAMZA receives third FDA approval
Subscribe for More Information
08:26 EDTPNRPentair to host conference call
Subscribe for More Information
06:55 EDTCTCMCTC Media volatility increases as Russian stocks trade lower
Subscribe for More Information
December 15, 2014
16:33 EDTLLYEli Lilly raises quarterly dividend 2% to 50c per share
Subscribe for More Information
16:07 EDTRXNRexnord initiated with a Buy at KeyBanc
Subscribe for More Information
December 12, 2014
12:52 EDTLLYEli Lilly: FDA expands approved use of Cyramza to treat lung cancer
Subscribe for More Information
December 11, 2014
10:13 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:40 EDTLLYEli Lilly upgraded at Morgan Stanley
As previously reported, Morgan Stanley upgraded Eli Lilly two notches to Overweight from Underweight. The firm has increased confidence in Eli Lilly's pipeline investments following recent external data in Alzheimer's and atherosclerosis and now expects potential evacetrapib peak sales of $3B and solanezumab peak sales of $10B. Price target raised to $85 from $60.
06:22 EDTLLYEli Lilly upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
06:11 EDTRXNJanus Capital reports 10.6% passive stake in Rexnord
Subscribe for More Information
December 10, 2014
12:20 EDTRUSHAAncora Advisors sends letter to Rush Enterprises board
Subscribe for More Information
07:53 EDTTVUBS to hold a conference
Subscribe for More Information
07:38 EDTPNRPentair authorizes $1B share repurchase program
Pentair's board has authorized the company to repurchase up to $1B of its common shares. The authorization allows the company to commence share repurchases effective immediately and expires on December 31, 2019.
07:37 EDTPNRPentair announces raises annual dividend by 16% to $1.28 per share
Subscribe for More Information
December 9, 2014
13:30 EDTTTMTata Motors' Jaguar recalls 7,000 F-Type cars, Reuters says
Subscribe for More Information
07:44 EDTLLYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:11 EDTLLYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use